Northern RNA is a full‑service CDMO that designs, develops, and manufactures DNA plasmids, high‑purity mRNA, cap analogs, and lipid nanoparticle (LNP) formulations for research, GLP, and GMP applications. Leveraging proprietary bioprocessing and chemical technologies, the company offers flexible batch sizes, comprehensive analytical testing, and regulatory documentation to support rapid prototyping, scale‑up, and clinical‑grade fill‑finish of nucleic acid therapeutics.
Funding
Funding not disclosed
Founders
Product
Problem
Researchers and developers of nucleic acid therapeutics face limited access to reliable, end‑to‑end manufacturing services that can handle complex plasmid constructs, high‑purity mRNA production, and lipid nanoparticle formulation at both research and GMP scales. This hampers rapid development, scale‑up, and regulatory compliance for vaccines, gene therapies, and other RNA‑based treatments.
Solution
Northern RNA operates as a full‑service CDMO offering design, development, and manufacturing of DNA plasmids, mRNA, cap analogs, and lipid nanoparticle (LNP) formulations. The company leverages proprietary bioprocessing and chemical technologies, along with a skilled workforce, to produce research‑grade, GLP, and GMP‑grade nucleic acid products. Clients receive traceable documentation, analytical testing, and regulatory support throughout the pipeline, from construct optimization to fill‑finish of clinical batches. Flexible production volumes—from milliliter‑scale hand fills to larger GMP runs—enable rapid prototyping and scale‑up for pre‑clinical, clinical, and commercial programs. Integrated LNP services, including microfluidic mixing, T/Y rapid mixing, and lyophilization, ensure efficient delivery of RNA therapeutics.
Target Audience
Primary customers are biotech and pharmaceutical companies developing mRNA vaccines, gene‑therapy vectors, and RNA‑based therapeutics, as well as academic and contract research organizations requiring high‑quality nucleic acid reagents and LNP formulation services.
Features
- Custom plasmid DNA production (research, GLP, GMP) with expertise in complex constructs such as tandem repeats, GC‑rich and highly structured regions
- High‑purity mRNA synthesis with proprietary Co Cap™A cap analogs available in research and GMP grades to enhance translational efficiency and stability
- End‑to‑end LNP formulation services, including in‑house ionizable lipid manufacturing, microfluidic mixing, and lyophilization for scalable delivery systems
- Comprehensive analytical testing suite (DLS, zeta potential, encapsulation efficiency, HPLC, endotoxin, bioburden, stability studies) with method development support
- cGMP‑compliant cleanroom suites (Grade C and Grade B aseptic filling) and validated vial configurations for clinical‑grade fill‑finish
- Flexible batch sizing from 0.5 mL hand fills to 60 mL automated fills, supporting early‑phase trials and individualized therapeutics
- Proprietary cap analog manufacturing (Co Cap™A) with batch‑to‑batch consistency, available in custom sizes and salt forms
- Integrated regulatory assistance and full documentation to meet clinical and commercial compliance requirements